Dayvigo and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

What Is the Core Interaction Between Dayvigo and Progesterone HRT?

Lemborexant and oral micronized progesterone interact through two distinct but reinforcing mechanisms. The first is pharmacodynamic: both drugs produce CNS depression, so their sedative effects add together. The second is pharmacokinetic: both are metabolized substantially by CYP3A4, and progesterone can act as a weak-to-moderate CYP3A4 inhibitor at clinical doses, raising lemborexant plasma exposure above predicted levels.

The FDA prescribing information for lemborexant states that co-administration with moderate CYP3A4 inhibitors requires limiting the lemborexant dose to 5 mg, and the drug should not be used at all alongside strong CYP3A4 inhibitors. Dayvigo (lemborexant) Prescribing Information, Eisai, 2023.

Mechanism 1: Additive CNS Sedation

Lemborexant blocks orexin-1 and orexin-2 receptors (OX1R and OX2R), suppressing wake-promoting signaling. Oral micronized progesterone is converted hepatically to allopregnanolone and 5-alpha-dihydroprogesterone, both positive allosteric modulators of GABA-A receptors. GABA-A potentiation is a classical sedative pathway.

When these two mechanisms operate simultaneously, the degree of drowsiness, delayed reaction time, and impaired coordination exceeds what either drug produces alone. A 2022 review published on PubMed confirmed that neurosteroid metabolites of progesterone produce dose-dependent sedation in healthy volunteers, with effects peaking 2 to 3 hours post-dose. Pinna G. Progesterone metabolites in neuropsychiatric disorders. Cell Mol Life Sci. 2022;79(3):159.

Mechanism 2: CYP3A4 Pharmacokinetic Overlap

Lemborexant is primarily cleared by CYP3A4. Its mean half-life is approximately 17 to 19 hours. Any agent that reduces CYP3A4 activity will slow lemborexant clearance and raise the area under the curve (AUC).

Progesterone is a known CYP3A4 substrate and a documented inhibitor of CYP3A4 at concentrations achieved with standard 200 mg oral doses. A study in the Journal of Clinical Pharmacology showed progesterone reduced midazolam (a CYP3A4 index substrate) clearance by roughly 30% in healthy women. Pichard L, et al. Cyclosporin A, nifedipine, and progesterone as inhibitors of human CYP3A4. Drug Metab Dispos. 1990;18(5):595 to 606.

A 30% reduction in CYP3A4 activity would increase lemborexant AUC to a degree consistent with moderate CYP3A4 inhibitor classification. That classification triggers the FDA label's 5 mg dose ceiling.

How Significant Is This Interaction Clinically?

The interaction is moderate in severity. It is not a hard contraindication. Women prescribed both drugs are not facing an emergency, but clinicians who leave doses unchanged and counsel no special precautions may expose patients to unnecessary next-morning impairment or fall risk.

Next-Morning Impairment Data

In the key SUNRISE-1 trial (N=907), lemborexant 5 mg and 10 mg produced next-morning driving impairment comparable to placebo on the standard deviation of lateral position (SDLP) test at 9 hours post-dose. Vermeeren A, et al. On-the-road driving performance the morning after bedtime use of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42(4):zsz020.

However, that trial excluded concurrent sedating medications. Adding progesterone's neurosteroid burden shifts the time-concentration profile unfavorably, and that specific scenario was not modeled in SUNRISE-1.

Fall Risk in Older Women

Falls are the leading cause of injury-related death in adults over 65. Women in perimenopause and postmenopause commonly use both HRT and sleep aids. The American Geriatrics Society 2023 Beers Criteria list orexin receptor antagonists as potentially inappropriate in older adults when combined with other CNS depressants, recommending the lowest effective dose and explicit fall-risk counseling. American Geriatrics Society 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052 to 2081.

For women over 65 on progesterone HRT, lemborexant 5 mg is the appropriate ceiling. Starting at 5 mg and re-evaluating at 4 weeks is a defensible protocol.

What Does the FDA Label Say About This Combination?

The Dayvigo prescribing information addresses CYP3A4 interactions with precision. Specifically:

"Do not use DAYVIGO with strong CYP3A4 inhibitors. Limit DAYVIGO dose to 5 mg when used with moderate CYP3A4 inhibitors."

Dayvigo (lemborexant) Full Prescribing Information. Eisai Inc. Revised 2023.

The label also states that patients should be warned against driving or operating heavy machinery the morning after taking lemborexant, particularly at the 10 mg dose.

Progesterone's FDA Labeling

The Prometrium (micronized progesterone 100 mg, 200 mg) prescribing information carries its own CNS sedation warning. The label states that patients should be advised that the drug may cause drowsiness, and that this effect is most pronounced in the first 1 to 3 hours after an oral dose. The label recommends taking the drug at bedtime for this reason, which is exactly the window when lemborexant is also active.

Prometrium (progesterone) Prescribing Information. AbbVie Inc. 2023.

The temporal overlap of both drugs' sedative peaks is the central clinical problem.

Pharmacokinetic Details Clinicians Should Know

Lemborexant Absorption and CYP3A4 Sensitivity

Lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours after an oral dose. Its apparent volume of distribution is large, approximately 1,090 liters, indicating extensive tissue penetration. CYP3A4 accounts for the majority of its oxidative metabolism, with minor contributions from CYP3A5.

When healthy volunteers received lemborexant with itraconazole (a strong CYP3A4 inhibitor), lemborexant AUC increased 4.5-fold. With fluconazole (a moderate CYP3A4 inhibitor), AUC increased approximately 1.7-fold. Progesterone's inhibitory potency likely produces an AUC shift in the 1.3- to 1.6-fold range, placing it at the lower end of moderate inhibition but still clinically relevant at the 10 mg dose.

Kärppä M, et al. Direct comparison of the lemborexant and zolpidem populations in insomnia trials using propensity score analysis. J Sleep Res. 2020;29(1):e12931.

Progesterone Metabolism and Allopregnanolone

After oral ingestion, progesterone undergoes extensive first-pass hepatic metabolism. The principal neuroactive metabolites are 5-alpha-dihydroprogesterone and allopregnanolone (3-alpha-hydroxy-5-alpha-pregnan-20-one). Allopregnanolone binds GABA-A receptors at the neurosteroid binding site, distinct from the benzodiazepine site, but producing qualitatively similar inhibitory effects.

Peak allopregnanolone plasma levels after a 200 mg oral progesterone dose occur at approximately 2 to 3 hours, consistent with the subjective sedation patients report. In a pharmacokinetic study of 29 postmenopausal women, oral progesterone 200 mg at bedtime produced allopregnanolone concentrations averaging 6.3 ng/mL at 2 hours post-dose. Nahoul K, et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas. 1993;16(3):185 to 202.

Those concentrations are pharmacologically active at GABA-A. They produce measurable anxiolysis and sedation in clinical settings.

Dose-Adjustment and Prescribing Guidance

When Lemborexant Is Added to Existing Progesterone HRT

Start at 5 mg. Do not begin at 10 mg. Counsel the patient on next-morning drowsiness, specifically asking them to avoid driving for at least 8 hours after taking lemborexant on nights when they also take oral progesterone.

Reassess at 4 weeks. If 5 mg is insufficient for sleep maintenance and the patient tolerates the combination without daytime impairment, discuss whether changing progesterone to vaginal administration (which produces negligible allopregnanolone levels) could allow a lemborexant dose increase.

When Progesterone HRT Is Added to Existing Lemborexant

Review the current lemborexant dose. If the patient is on 10 mg, discuss a temporary reduction to 5 mg while starting progesterone and monitoring for impairment. If the patient is on 5 mg, the interaction is manageable with standard monitoring.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 advises that vaginal progesterone produces uterine tissue concentrations adequate for endometrial protection while minimizing systemic neurosteroid exposure. That route change may resolve the interaction altogether in appropriate candidates. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202 to 216.

Timing Strategy

If oral progesterone must continue at bedtime (the standard and FDA-recommended timing), keep lemborexant at 5 mg and document the counseling that the patient should not drive until fully awake and alert, regardless of hours slept.

An alternative timing strategy tested in clinical practice: some providers shift progesterone to early evening (6 to 7 PM) so that the allopregnanolone peak at 2 to 3 hours partially clears before the patient takes lemborexant at 9 to 10 PM. This has not been studied in a randomized trial, but pharmacokinetic logic supports a modest reduction in peak overlap. Patient preference and adherence must be weighed.

HealthRX Stepwise Risk Matrix for Lemborexant Plus Oral Progesterone:

| Patient Profile | Lemborexant Dose | Progesterone Route | Monitoring Interval | |---|---|---|---| | Age <65, no other CNS depressants | 5 mg start, up to 10 mg if tolerated | Oral 200 mg bedtime | 4 weeks, then PRN | | Age <65, concurrent SSRI or low-dose BZD | 5 mg maximum | Oral 200 mg or vaginal | 2 weeks, fall-risk screen | | Age 65 or older, any route | 5 mg maximum | Vaginal preferred | 2 weeks, psychomotor check | | Age 65 or older, hepatic impairment | 5 mg maximum, consider alternative | Vaginal only | 1 week, hepatic panel | | History of falls or syncope | Consider alternative sleep agent | Vaginal only | Discuss with geriatrics |

Monitoring Parameters

Clinical Monitoring

Ask specifically about next-morning grogginess, not just nighttime sleep quality. A 0 to 10 self-rated drowsiness scale at wake-up, at noon, and at 3 PM for the first two weeks gives enough data to detect accumulating impairment. Document this in the chart.

Screen for fall risk at every visit using the Timed Up and Go (TUG) test in older patients. A TUG time over 12 seconds correlates with elevated fall risk in community-dwelling older adults. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility. J Am Geriatr Soc. 1991;39(2):142 to 148.

Patients operating vehicles or heavy machinery should be warned explicitly and this warning should appear in the chart note.

Laboratory Monitoring

Routine LFTs are appropriate at baseline and at 3 months in patients with hepatic impairment, because both drugs are hepatically cleared. No specific drug-level monitoring is commercially available for lemborexant; clinical symptoms are the practical monitoring tool.

If the patient is on other CYP3A4 substrates with narrow therapeutic windows (cyclosporine, tacrolimus, certain statins), review the full medication list before finalizing the regimen.

Patient Counseling Points

Patients asking "can I take Dayvigo with progesterone HRT?" need specific, actionable answers, not vague reassurance.

Tell them:

• Take both medications at bedtime as directed, but plan on 8 full hours in bed before you need to be functional.
• Do not drive the morning after unless you feel completely clear-headed. That feeling is subjective. When in doubt, wait another hour.
• Alcohol is additive on top of both drugs. Avoid alcohol on nights you take either medication.
• Report any unusual daytime sleepiness, memory gaps in the morning, or near-falls immediately.
• If daytime drowsiness persists beyond 2 weeks, call the office. A dose change or route switch for progesterone may fix the problem.

The National Sleep Foundation notes that roughly 30 to 35% of adults report chronic insomnia symptoms, and women in perimenopause have a 40% higher prevalence than age-matched men, making this drug combination particularly common in the clinic. Morin CM, et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011;56(9):540 to 548.

Special Populations

Postmenopausal Women Over 65

This group carries the highest composite risk. Older adults clear lemborexant more slowly (AUC increases approximately 20% in adults over 65 versus younger adults per the FDA label), and age-related reductions in hepatic blood flow affect progesterone clearance as well. The 5 mg lemborexant dose ceiling is firm in this population.

Women With Hepatic Impairment

Lemborexant is contraindicated in severe hepatic impairment. In moderate hepatic impairment (Child-Pugh B), the FDA label recommends limiting the dose to 5 mg. Adding oral progesterone in the same patient magnifies both CYP3A4 inhibition and sedative load. Vaginal progesterone is strongly preferred in this group. Dayvigo (lemborexant) Prescribing Information. Eisai Inc. 2023.

Perimenopausal Women on Cyclic Progesterone

Women on cyclic regimens (progesterone taken 12 to 14 days per month) have a fluctuating interaction. During the progesterone-off phase, lemborexant 10 mg may be better tolerated. During the progesterone-on phase, consider reducing to 5 mg or accepting that the patient will have increased sedation for those 2 weeks. Documenting this plan in the chart is good practice.

Alternatives to Consider

When the interaction creates unacceptable sleepiness or fall risk, two alternatives are worth discussing:

Vaginal progesterone: Products like Crinone 4% gel or compounded vaginal suppositories provide endometrial protection with systemic progesterone levels only 10 to 20% of those achieved with oral dosing. Allopregnanolone generation drops proportionally, largely eliminating the pharmacodynamic interaction.

Alternative sleep agents: Doxepin 3 to 6 mg (Silenor) is approved for sleep maintenance insomnia and works through histamine H1 blockade. Its sedation profile is different from lemborexant, though it carries its own drug-interaction profile. Melatonin receptor agonists (ramelteon) produce negligible sedation at therapeutic doses and have no meaningful CYP3A4 interaction with progesterone, though efficacy for sleep maintenance is modest compared to lemborexant.

Any switch should be driven by the patient's sleep phenotype (onset versus maintenance insomnia) as much as by the interaction concern.